DAT-1604
/ Danatlas
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 02, 2025
Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DAT-1604 in Advanced Solid Tumor
(clinicaltrials.gov)
- P1 | N=228 | Not yet recruiting | Sponsor: Danatlas Pharmaceuticals Co., Ltd
Monotherapy • New P1 trial • Solid Tumor
1 to 1
Of
1
Go to page
1